

- after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *N. Engl. J. Med.* 2017; 377(20): 1919–1929. <https://doi.org/10.1056/NEJMoa1709937>.
19. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchar d D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. *J Thorac Oncol* 2020; 15(2): 288–293. <https://doi.org/10.1016/j.jtho.2019.10.002>.
20. Faivre-Finn C, Vicente D, Kurata T, Planchar d D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu Y-L, Gray JE, Özgüroğlu M, Lee KH, Newton M, Wang L, Thiyagarajah P, Antonia SJ. LBA49 Durvalumab after Chemoradiotherapy in Stage III NSCLC: 4-Year Survival Update from the Phase III PACIFIC Trial. *Annals of Oncology* 2020; 31: S1178–S1179. <https://doi.org/10.1016/j.annonc.2020.08.2281>.
21. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchar d D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018; 379(24): 2342–2350. <https://doi.org/10.1056/NEJMoa1809697>.
22. Faivre-Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis PA, Antonia SJ. 1363O Efficacy and Safety Evaluation Based on Time from Completion of Radiotherapy to Randomization with Durvalumab or Placebo in Pts from PACIFIC. *Ann Oncol* 2018; 29(suppl\_8). <https://doi.org/10.1093/annonc/mdy291>.
23. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchar d D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018; 379(24): 2342–2350. <https://doi.org/10.1056/NEJMoa1809697>.
24. European Medical Agency. Imfinzi: Summary of Product Characteristics. <https://www.ema.europa.eu/En/Documents/Product-Inf>.
25. FDA Approves Additional Dosing Option of Durvalumab for Stage III NSCLC, Advanced Bladder Cancer <https://www.cancernetwork.com/view/fda-approves-additional-dosing-option-of-durvalumab-for-stage-iii-nsclc-advanced-bladder-cancer> (accessed Nov 29, 2020).
26. Imfinzi-Epar-Product-Information\_cs.Pdf.
27. Durm GA, Althouse SK, Sadiq AA, Jalal SI, Jabbour S, Zon R, Kloecker GH, Fisher WB, Reckamp KL, Kio EA, Langdon RM, Adesunloye B, Gentzler RD, Hanna NH. Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN 14-179. *JCO* 2018; 36(15\_suppl): 8500–8500. [https://doi.org/10.1200/JCO.2018.36.15\\_suppl.8500](https://doi.org/10.1200/JCO.2018.36.15_suppl.8500).